Smith & Nephew SNATS, Inc. $SNN Holdings Trimmed by Deprince Race & Zollo Inc.

Deprince Race & Zollo Inc. lowered its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 37.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 339,883 shares of the medical equipment provider’s stock after selling 201,839 shares during the period. Deprince Race & Zollo Inc. owned about 0.08% of Smith & Nephew SNATS worth $12,334,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SNN. AlphaCore Capital LLC acquired a new position in Smith & Nephew SNATS in the second quarter worth approximately $44,000. Banque Transatlantique SA bought a new stake in shares of Smith & Nephew SNATS during the 1st quarter worth $52,000. Bessemer Group Inc. boosted its stake in shares of Smith & Nephew SNATS by 111.9% during the 2nd quarter. Bessemer Group Inc. now owns 3,709 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 1,959 shares in the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Smith & Nephew SNATS by 15.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,149 shares of the medical equipment provider’s stock worth $118,000 after acquiring an additional 541 shares during the last quarter. Finally, MAI Capital Management raised its position in shares of Smith & Nephew SNATS by 24.0% during the second quarter. MAI Capital Management now owns 4,371 shares of the medical equipment provider’s stock worth $134,000 after purchasing an additional 846 shares during the period. 25.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on SNN shares. Royal Bank Of Canada lowered Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Monday, December 22nd. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Finally, Sanford C. Bernstein set a $37.50 price target on Smith & Nephew SNATS and gave the company a “market perform” rating in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Smith & Nephew SNATS has an average rating of “Hold” and a consensus price target of $35.75.

Smith & Nephew SNATS Price Performance

NYSE SNN opened at $33.01 on Monday. Smith & Nephew SNATS, Inc. has a fifty-two week low of $23.69 and a fifty-two week high of $38.79. The stock’s 50-day moving average is $33.85 and its two-hundred day moving average is $33.93. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.